Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Brain health: time matters in multiple sclerosis.

Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T.

Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48. doi: 10.1016/j.msard.2016.07.003. Review.

2.

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK.

Mult Scler. 2016 Jun 30. pii: 1352458516657441. [Epub ahead of print]

PMID:
27364322
3.

An investigation of commonly prescribed stretches of the ankle plantarflexors in people with Multiple Sclerosis.

Ofori J, Freeman J, Logan A, Rapson R, Zajieck J, Hobart J, Marsden J.

Clin Biomech (Bristol, Avon). 2016 Aug;37:22-6. doi: 10.1016/j.clinbiomech.2016.05.013.

PMID:
27286554
4.

Measuring spinal surgical success: the proportion achieving acceptable symptoms: Keep it simple but not simplistic.

Hobart J.

Spine J. 2016 Apr;16(4 Suppl):S19-20. doi: 10.1016/j.spinee.2016.01.221.

PMID:
26996054
5.

Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.

Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Watson C.

Value Health. 2015 Nov;18(7):A713. doi: 10.1016/j.jval.2015.09.2688. No abstract available.

6.

Measuring the Impact of Multiple Sclerosis: Enhancing the Performance of the Msis-29 and Msws-12.

Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Watson C.

Value Health. 2015 Nov;18(7):A709-10. doi: 10.1016/j.jval.2015.09.2670. No abstract available.

7.

Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.

Walton MK, Powers JH 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S, Isaac M, Molsen E, Cano S, Burke LB; International Society for Pharmacoeconomics and Outcomes Research Task Force for Clinical Outcomes Assessment..

Value Health. 2015 Sep;18(6):741-52. doi: 10.1016/j.jval.2015.08.006.

8.

Measuring arm function early after stroke: is the DASH good enough?

Baker K, Barrett L, Playford ED, Aspden T, Riazi A, Hobart J.

J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):604-10. doi: 10.1136/jnnp-2015-310557.

PMID:
26180212
9.

People receiving unnecessary treatments: accurate diagnosis is key.

Germon T, Hobart J.

BMJ. 2015 Jun 2;350:h2962. doi: 10.1136/bmj.h2962. No abstract available.

PMID:
26036430
10.

Definitions, diagnosis, and decompression in spinal surgery: problems and solution.

Germon TJ, Hobart JC.

Spine J. 2015 Mar 2;15(3 Suppl):S5-8. doi: 10.1016/j.spinee.2014.12.147. No abstract available.

PMID:
25708140
11.

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.

Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

12.

Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis?

Barrett L, Cano S, Zajicek J, Hobart J.

Mult Scler. 2015 Apr;21(5):612-21. doi: 10.1177/1352458514549396.

PMID:
25583836
13.

Is NICE guidance for identifying lumbar nerve root compression misguided?

Germon T, Singleton W, Hobart J.

Eur Spine J. 2014 Apr;23 Suppl 1:S20-4. doi: 10.1007/s00586-014-3233-y.

14.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC)., Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2).; International IBD Genetics Consortium (IIBDGC)., Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770.

15.

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.

Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Gomez Cano M, McManus D, Mallik S, Hobart J; CUPID investigator group..

Lancet Neurol. 2013 Sep;12(9):857-65. doi: 10.1016/S1474-4422(13)70159-5. Review.

16.

A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.

Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium.; Wellcome Trust Case Control Consortium,2., Romano S, Salvetti M, Ristori G.

PLoS One. 2013 May 16;8(5):e63300. doi: 10.1371/journal.pone.0063300.

17.

Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis.

Hobart J, Cano S, Baron R, Thompson A, Schwid S, Zajicek J, Andrich D.

Mult Scler. 2013 Nov;19(13):1773-83. doi: 10.1177/1352458513483378.

PMID:
23574800
18.

Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.

Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.

Neurology. 2013 Apr 16;80(16):1509-17. doi: 10.1212/WNL.0b013e31828cf7f3. Review.

PMID:
23535489
19.

Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures.

Freeman J, Walters R, Ingram W, Slade A, Hobart J, Zajicek J.

Mult Scler. 2013 Oct;19(12):1632-9. doi: 10.1177/1352458513482373.

PMID:
23530002
20.

Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.

Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, Zajicek J, Hobart J; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2013 Feb;9(1 Suppl):S56-60. doi: 10.1016/j.jalz.2012.10.008.

PMID:
23391006
Items per page

Supplemental Content

Loading ...
Support Center